133 related articles for article (PubMed ID: 23163037)
1. [Technological approaches to development of whole-virion inactivated vaccine from recombinant strain against A/H5N1 influenza in the Republic of Kazakhstan].
Kydyrbaev ZhK; Mamadaliev SM; Asanzhanova NN; Tabynov KK; Ryskel'dinova ShZh; Cherviakova OV; Sandybaev NT; Khaĭrullin BM; Kiselev OI
Zh Mikrobiol Epidemiol Immunobiol; 2012; (5):54-9. PubMed ID: 23163037
[TBL] [Abstract][Full Text] [Related]
2. An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.
Sansyzbay AR; Erofeeva MK; Khairullin BM; Sandybayev NT; Kydyrbayev ZK; Mamadaliyev SM; Kassenov MM; Sergeeva MV; Romanova JR; Krivitskaya VZ; Kiselev OI; Stukova MA
Clin Vaccine Immunol; 2013 Aug; 20(8):1314-9. PubMed ID: 23803900
[TBL] [Abstract][Full Text] [Related]
3. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
Ninomiya A; Imai M; Tashiro M; Odagiri T
Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
[TBL] [Abstract][Full Text] [Related]
4. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations.
Miyaki C; Quintilio W; Miyaji EN; Botosso VF; Kubrusly FS; Santos FL; Iourtov D; Higashi HG; Raw I
Vaccine; 2010 Mar; 28(13):2505-9. PubMed ID: 20123051
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.
Lin J; Zhang J; Dong X; Fang H; Chen J; Su N; Gao Q; Zhang Z; Liu Y; Wang Z; Yang M; Sun R; Li C; Lin S; Ji M; Liu Y; Wang X; Wood J; Feng Z; Wang Y; Yin W
Lancet; 2006 Sep; 368(9540):991-7. PubMed ID: 16980114
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
7. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection.
Ikeno D; Kimachi K; Kino Y; Harada S; Yoshida K; Tochihara S; Itamura S; Odagiri T; Tashiro M; Okada K; Miyazaki C; Ueda K
Microbiol Immunol; 2010 Feb; 54(2):81-8. PubMed ID: 20377741
[TBL] [Abstract][Full Text] [Related]
9. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the efficacy of an adjuvant-based inactivated pandemic H5N1 influenza virus vaccine.
Nurpeisova A; Kassenov M; Rametov N; Tabynov K; Renukaradhya GJ; Volgin Y; Sagymbay A; Makbuz A; Sansyzbay A; Khairullin B
Arch Virol; 2019 Apr; 164(4):1027-1036. PubMed ID: 30740636
[TBL] [Abstract][Full Text] [Related]
11. A/H5N1 prepandemic influenza vaccine (whole virion, vero cell-derived, inactivated) [Vepacel®].
Plosker GL
Drugs; 2012 Jul; 72(11):1543-57. PubMed ID: 22788239
[TBL] [Abstract][Full Text] [Related]
12. [Comparative clinical trial of vaccines against avian influenza].
Zverev VV; Katlinskiĭ AV; Kostinov MP; Zhirova SN; Erofeeva MK; Stukova MA; Korovkin SA; Mel'nikov SIa; Semchenko AV; Mironov AN
Zh Mikrobiol Epidemiol Immunobiol; 2007; (3):10-6. PubMed ID: 17672124
[TBL] [Abstract][Full Text] [Related]
13. Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin.
Sawai T; Itoh Y; Ozaki H; Isoda N; Okamoto K; Kashima Y; Kawaoka Y; Takeuchi Y; Kida H; Ogasawara K
Immunology; 2008 Jun; 124(2):155-65. PubMed ID: 18205793
[TBL] [Abstract][Full Text] [Related]
14. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
[TBL] [Abstract][Full Text] [Related]
15. Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine.
Geeraedts F; ter Veer W; Wilschut J; Huckriede A; de Haan A
Vaccine; 2012 Oct; 30(45):6501-7. PubMed ID: 22841974
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement.
Ruat C; Caillet C; Bidaut A; Simon J; Osterhaus AD
J Virol; 2008 Mar; 82(5):2565-9. PubMed ID: 18094159
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits.
Heldens JG; Glansbeek HL; Hilgers LA; Haenen B; Stittelaar KJ; Osterhaus AD; van den Bosch JF
Vaccine; 2010 Nov; 28(51):8125-31. PubMed ID: 20950729
[TBL] [Abstract][Full Text] [Related]
20. The avian influenza vaccine Emerflu. Why did it fail?
Young BE; Sadarangani SP; Leo YS
Expert Rev Vaccines; 2015; 14(8):1125-34. PubMed ID: 26098721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
